logo-loader

Northland Capital Partners View on the City - Hemogenyx

Published: 22:41 24 Jan 2019 AEDT

no_picture_pai

HEMOGENYX PLC (LON:HEMO)

SECTOR – HEALTHCARE

RATING – CORP*

MARKET CAP – £10.9m

CURRENT PRICE – 2.9p#

ANALYSTS: LIAM GASCOIGNE-COHEN

 

Year-end Dec

2016A

2017A

2018E

2019E

2020E

 

Revenue (£m)

-

-

No forecasts provided

EBITDA (£m)

(0.5)

(2.3)

Pre-tax profit (£m)

(0.5)

(2.4)

EPS (p)

(0.00)

(0.01)

DPS (p)

-

-

Net Cash/(Debt) (£m)

(0.2)

 1.9

P/E (x)

-

-

Dividend yield (%)

-

-

EV/EBITDA (x)

-

-

 

SOURCE: Northland Capital Partners Limited estimates. #Priced at prior trading day close. *Northland Capital Partners Limited provides acts as Joint Broker to Hemogenyx plc and therefore this information should be viewed as a Marketing Communication.

 

Initiation of research: Disrupting current blood disease therapy (Note attached)

 

NORTHLAND VIEW

Hemogenyx is a biotechnology company quoted on the LSE Standard List. The Company is developing novel therapies for blood diseases which aim to offer a safer and more accessible patient pathway than current practice. Although the products are at the preclinical stage, the Company is already generating revenue through multiple collaborations with biopharmaceutical companies.

  • Modular platform technology: The Company is developing two products including an immunotherapy product (CDX Ab) for patient conditioning and a cell therapy (Hu-PHEC) for bone-marrow transplants.

  • Clear Milestones: With an established proof-of-principle for its CDX antibody platform, the Company is targeting the start of clinical trials in 2019.

  • Revenue-generating collaborations: With collaboration agreements signed across its pipeline, the Company is leveraging its platforms with large industry players to accelerate development and share the cost of development. This represents a strong validation of the Group’s products.

Although the Company has demonstrated strong progress across its pipeline, the share price remains below its IPO price of 3.5p/share. With multiple collaboration agreements and investment from industry we view the Company as undervalued.

 

 

COMPANY DESCRIPTION

Preclinical stage biotechnology company focused on the development of novel therapies for blood diseases.

 

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

13 hours, 13 minutes ago